¼¼ºê¶õ½ºº´¿ø Next Generation Precision medicine: Bridging biology and drug development in precision oncology : 2019-11-01±³À°ÀÏÀÚ : 2019-11-01
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ 1Ãþ À¯ÀÏÇÑ È¦
±³À°ÁÖÁ¦ :
Next Generation Precision medicine: Bridging biology and drug development in precision oncologyÁÖÃÖ±â°ü : ¼¼ºê¶õ½ºº´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ³»°ú
´ã´çÀÚ : ÀÌÁ¤Àº
¿¬¶ôó : 02-2228-0613
À̸ÞÀÏ :
jelee220@yuhs.ac ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í ¡Þ ¼ö°·á: 20,000¿ø (»çÀüµî·Ï ±âÁØ) -¿¬¼¼ÀÇ·á¿ø Á÷¿ø ¹× Çлý ¹«·á -¿ÜºÎÀÎ °æ¿ì¿¡µµ ÇлýÀº ¹«·á -±âŸÀÇ °æ¿ì¿¡´Â ¼ö°·á ¡¼ö. ÇöÀåµî·Ï½Ã 3¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-01 ABMRC À¯ÀÏÇÑȦ 09:00~09:10 Opening and Welcome Address ()
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 09:10~09:30 Employing the dual nature of T cells for immunotherapy Yoon Park(KIST, Korea)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 09:30~09:50 NK cell-based immunotherapy for refractory cancer In Pyo Choi(KRIBB, Korea)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 09:50~10:30 Cancer genomics landscape for precision medicine and the future Alex Boussioutas(The University of Melbourne, Australia)
ÈÞ½Ä 11-01 ABMRC À¯ÀÏÇÑȦ 10:30~10:50 ()
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 10:50~11:20 Heading towards the SUMMIT of HER2 Mutations: Moving Cancer Knowledge Past HER2 Amplification Michael Cox(Puma Biotechnology, Inc., USA)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 11:20~11:50 Merck¡¯s approach to precision medicine in oncology Peter Tobin(Merck-Serono Co. Ltd., USA)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 11:50~13:00 New Era of Systemic Chemotherapy for Advanced Gastric Cancer Narikazu Boku(National Cancer Hospital, Japan)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 13:00~13:20 The promise of combining radiation therapy and immunotherapy Jee Suk Chang(Yonsei University College of Medicine, Korea)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 13:20~13:50 The BiTE¢ç immuno-oncology platform and its potential application in gastric Cancer Virginie Naegele(Amgen Research (Munich) GmbH, Germany)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 13:50~14:10 Exosomes and mimetic technologies for theranostics Yong Song Gho(POSTECH, Korea)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 14:10~14:30 AI and Precision Medicine: Data-driven drug response prediction and drug discovery Jae Woo Kang(Korea University, Korea)
ÈÞ½Ä 11-01 ABMRC À¯ÀÏÇÑȦ 14:30~14:50 ()
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 14:50~15:40 GI network, Omics, Georgetown John Marshall(Georgetown University Hospital, USA)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 15:40~16:00 Novel IO response predictive biomarker : Alex Boussioutas(The University of Melbourne, Australia)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 16:00~16:30 Anti-drug Ab with immune-oncologic agent in melanoma and lung cancer Aaron Ha(Sengenics Co., Ltd., Singapore)
±³À°½Ã°£ 11-01 ABMRC À¯ÀÏÇÑȦ 16:30~17:00 Epigenetic predictive biomarker of IO treatment Raghav Sundar(National University Hospital, Singapore)